Prophylactic Administration of Recombinant Human Thrombopoietin in the Secondary Prevention of Thrombocytopenia Induced by XELOX Adjuvant Chemotherapy in Patients With Stage III Colorectal Cancer

摘要

In 2013, approximately 348,000 patients with colorectal cancer (CRC) were treated in China, of whom 9.45% were newly diagnosed cases. The crude incidence and mortality of CRC was 25.57/100,000 (fourth most common cancer) and 12.11/100,000 (fifth deadliest cancer), respectively. According to the AJCC Cancer Staging System (eighth edition), XELOX (intravenous oxaliplatin and capecitabine intervention) is the recommended adjuvant chemotherapy regimen for patients with stage III CRC.